# Final Recommendation

## Decision Status

- Recommendation: `No-Go for production implementation`; proceed with a targeted gap-closure validation sprint.
- Go/No-Go: `no-go`
- Decision Date: `2026-02-25`

## Rationale Summary

- `VC-001`, `VC-003`, `VC-006`, and `VC-007` passed using direct P1 evidence, confirming baseline policy design, audit integrity posture, collaboration control model, and cost-governance definition.
- `VC-002`, `VC-004`, `VC-005`, and `VC-008` are partial because critical runtime replay evidence and key compliance/provenance closure artifacts are still missing.
- An unresolved critical risk (`RISK-003`) remains open; per validation rules, unresolved critical risk blocks go.

Primary evidence refs:
- `outputs/p1-research-execution/policy-plane-design.md`
- `outputs/p1-research-execution/provenance-audit-architecture.md`
- `outputs/p1-research-execution/runtime-workflow-architecture.md`
- `outputs/p1-research-execution/local-first-collaboration-architecture.md`
- `outputs/p1-research-execution/cost-and-capacity-model.md`
- `outputs/p1-research-execution/compliance-control-mapping.md`

## Unresolved Critical Risk Handling

`RISK-003` handling path (mandatory before go):
1. Completed: define VC-004/VC-005 reconnect/replay stress plan and evidence template (`validation-plan.md`, `validation-results.md`).
2. Completed: gather scope-gate evidence (`apps/web` baseline tests pass but runtime is explicitly throwaway and out of production-validation scope).
3. Completed: draft runtime contract artifact `RRC-001` for `platform-runtime-v1` (resume token, checkpoint correlation, idempotency fence, auth/policy revalidation).
4. Completed: define `RRC-001` implementation work package (`WP-RT-001..WP-RT-005`) and acceptance mapping.
5. Implement `RRC-001.v1` in the non-throwaway target runtime (`platform-runtime-v1`).
6. Execute reconnect/replay stress scenarios covering high-burst workflow interruption and resume behavior.
7. Produce evidence that side-effecting steps remain idempotent with zero critical duplicate-side-effect findings.
8. Update `validation-results.md`, `gap-analysis.md`, and `risk-register.md` with closure evidence.
9. Re-run decision review only after `RISK-003` status moves from `open` to `closed`.

Target review checkpoint for closure evidence: `2026-03-11`.

Execution forecast:
- Sprint 1 (`2026-02-26` to `2026-03-02`): contract and persistence foundations.
- Sprint 2 (`2026-03-03` to `2026-03-07`): replay/auth/policy/traceability hardening.
- Sprint 3 (`2026-03-08` to `2026-03-11`): RR campaign + closure report.

## Conditions to Switch to Go

All conditions are required:
- Close `GAP-RT-01` and `RISK-003`.
- Approve and implement `RRC-001.v1` in `platform-runtime-v1`.
- Close or downgrade `GAP-A1-01` and `RISK-004` with measured incident-playbook evidence.
- Close `GAP-PI1-01` with provenance exemplars for all high-risk workflow classes.
- Complete policy change-governance separation-of-duties implementation for `GAP-C6-01`.

## Deferred Items Accepted with Risk

- Specialized provider adoption (`aws-plus-specialized`) remains deferred; baseline recommendation remains `aws-dominant` unless future validated evidence shows material reliability/compliance benefit.
